Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy

Menopause

Volumn 21, Issue 3, 2014, Pages 309-319

  Pinkerton, Joann V ^a   Stanczyk, Frank Z ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Dyspareunia; Lasofoxifene; Ospemifene; Selective estrogen receptor modulators; Vaginal atrophy

Indexed keywords

ARZOXIFENE; BAZEDOXIFENE; CENTCHROMAN; CONJUGATED ESTROGEN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOLLITROPIN; LASOFOXIFENE; OSPEMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING PROTEIN; TAMOXIFEN;

DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSPAREUNIA; EMBASE; ESTROGEN THERAPY; FEMALE; HUMAN; MATURATION; MEDLINE; NONHUMAN; PATHOPHYSIOLOGY; PELVIC ORGAN PROLAPSE; PH; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TARGET CELL; VAGINA ATROPHY; VAGINAL MATURATION INDEX; VENOUS THROMBOEMBOLISM; VULVA DISEASE; VULVAR AND VAGINAL ATROPHY;

ATROPHY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; PELVIC ORGAN PROLAPSE; POSTMENOPAUSE; PYRROLIDINES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA; VULVAR DISEASES;

EID: 84896712271     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31829755ed     Document Type: Review

References (95)

1. Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophyY related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 2012;19:109-117.
2. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142.
3. Simon JA. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health (Larchmt) 2011; 20:1453-1465.
4. Kingsberg S, Wysocki S, Magnus L, Krychman M. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) Survey [epub ahead of print]. J Sex Med 2013.
5. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; CD001500.
6. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(suppl 1):s1-s66.
7. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12:91-105.
8. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril 2006;85:155-160.
9. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
10. Cano A, Estevez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 2012;19:1130-1139.
11. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-36.
12. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000;295: 431-437.
13. Taylor HS. Designing the ideal selective estrogen receptor modulatorV an achievable goal? Menopause 2009;16:609-615.
14. Tee MK, Rogatsky I, Tzagarakis-Foster C, et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors > and A. Mol Biol Cell 2004;15:1262-1272.
15. Osphena [package insert]. Florham Park, NJ: Shionogi Inc.; 2013.
16. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361-372.
17. McCall JL, DeGregorio MW. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol 2010;6:773-779.
18. Evista [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.
19. Nath A, Sitruk-Ware R. Pharmacology and clinical applications of selective estrogen receptor modulators. Climacteric 2009;12:188-205.
20. Wiebe VJ, Benz CC, DeGregorio MW. Clinical pharmacokinetics of drugs used in the treatment of breast cancer. Clin Pharmacokinet 1988; 15:180-193.
21. Ouellet D, Bramson C, Roman D, et al. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. Br J Clin Pharmacol 2007;63:59-66.
22. Rosati RL, Da Silva JP, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998; 41:2928-2931.
23. Ermer J, McKeand W, Sullivan P. Bazedoxifene acetate dose proportionality in healtly, postmenopausal women. Clin Pharmacol Ther 2003; 73:46.
24. Patat A, McKeand W, Baird Bellaire S, Ermer J, LeCoz F. Absolute/relative bioavailability of bazedoxifene acetate in health postmenopausal women. Clin Pharmacol Ther 2003;73:43.
25. Prakash C, Johnson KA, Schroeder CM, Potchoiba MJ. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys. Drug Metab Dispos 2008;36:1753-1769.
26. European Medicines Agency. Assessment Report for Fablyn (Lasofoxifene; EMEA/14045/2009). London, England: EMEA; 2009.
27. Gennari L. Ospemifene Hormos. Curr Opin Investig Drugs 2004;5:448-455.
28. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor > and estrogen receptor A to partial estrogen agonists/antagonists. Mol Pharmacol 1998;54:105-112.
29. Anker GB, Lonning PE, Aakvaag A, Lien EA. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scand J Clin Lab Invest 1998;58:103-107.
30. Gjerde J, Geisler J, Lundgren S, et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 2010; 10:313.
31. Reindollar R, Koltun W, Parsons A, Rosen A, Siddhanti S, Plouffe L Jr. Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity. Fertil Steril 2002;78:469-472.
32. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809-820.
33. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43:207-214.
34. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998;139: 2068-2076.
35. Gardner M, Taylor A, Wei G, Calcagni A Jr, Duncan B, Milton A. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J Clin Pharmacol 2006;46:52-58.
36. Miller CP, Collini MD, Tran BD, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 2001;44:1654-1657.
37. Palacios S. Efficacy of bazedoxifene, pre-bisphosphonate sequential therapy for osteoporosis and the patient profile for bazedoxifene. Rev Osteoporos Metab Miner 2010;2(suppl 5):s19-s25.
38. Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006;24:314-318.
39. Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004;18:152-158.
40. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-696.
41. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-535.
42. Komm BS, Chines AA. Bazedoxifene: the evolving role of thirdgeneration selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis 2012;4:21-34.
43. Pickar JH, MacNeil T, Ohleth K. SERMs: progress and future perspectives. Maturitas 2010;67:129-138.
44. Diez JL. Skeletal effects of selective oestrogen receptor modulators (SERMs). Hum Reprod Update 2000;6:255-258.
45. Nolvadex [package insert]. Wilmington, DE: AstraZeneca; 2002.
46. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
47. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
48. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008.
49. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001;77:271-279.
50. Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4- hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause 2012;19:96-103.
51. Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111:650-656.
52. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137.
53. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and activecontrolled clinical trial. J Bone Miner Res 2008;23:1923-1934.
54. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480-486.
55. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Metaanalysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-947.
56. Simon T, Boutouyrie P, Simon JM, et al. Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation. 2002;106:2925-2929.
57. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009;119:922-930.
58. Ensrud K, LaCroix A, Thompson JR, et al. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation 2010;122:1716-1724.
59. Simon J, Lin V, Radovich C, Bachmann GA, The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2013;20:418-427.
60. Cerciat M, Unkila M, Garcia-Segura LM, Arevalo MA. Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gammaYinducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 2010;58:93-102.
61. Ciriza I, Carrero P, Azcoitia I, Lundeen SG, Garcia-Segura LM. Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. J Neurobiol 2004;61:209-221.
62. Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 2010;17: 642-653.
63. Portman DJ, Bachmann G, Simon J, The Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy [published online ahead of print January 28, 2013]. Menopause. doi:10.1097/gme.0b013e318279ba64.
64. Vardy MD, Lindsay R, Scotti RJ, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 2003; 189:81-88.
65. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005;12:202-209.
66. Portman D, Moffett A, Kerber I, Drosman S, Somayaji V, Lee A. Vaginal effects of lasofoxifene and raloxifene: preliminary evidence suggests lasofoxifene, but not raloxifene, improves indices of vaginal health (Abstract P-87). Menopause 2004;11:645.
67. Delmanto A, Nahas-Neto J, Nahas EA, de Oliveira ML, Fernandes CE, Traiman P. Effect of raloxifene on the vaginal epithelium of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2008;139:187-192.
68. Varras M, Polyzos D, Akrivis C. Effects of tamoxifen on the human female genital tract: review of the literature. Eur J Gynaecol Oncol 2003; 24:258-268.
69. Marttunen MB, Cacciatore B, Hietanen P, et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women. Br J Cancer 2001;84:897-902.
70. Kagan R. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms. J Womens Health (Larchmt) 2012;21:975-981.
71. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-1038.
72. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187:521-527.
73. Goldstein SR, Bhattoa HP, Neven P, et al. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. Menopause 2012;19:41-47.
74. Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging 2008;8:135-145.
75. Boccardo F, Bruzzi P, Rubagotti A, Nicolo GU, Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 1981;38:281-285.
76. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999;17:1488-1492.
77. Parsons A, Merritt D, Rosen A, Heath H III, Siddhanti S, Plouffe L Jr. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346-352.
78. Pinkerton JV, Shifren JL, La VJ, Rosen A, Roesinger M, Siddhanti S. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003;10: 45-52.
79. Kessel B, Nachtigall L, Plouffe L, Siddhanti S, Rosen A, Parsons A. Effect of raloxifene on sexual function in postmenopausal women. Climacteric 2003;6:248-256.
80. Stovall DW, Utian WH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14(pt 1):510-517.
81. Sharma S, Albertazzi P, Bottazzi M. The long-term effect of raloxifene on the genitourinary tract. Climacteric 2007;10:244-248.
82. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-1024.
83. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281-289.
84. Lilly Reports on Outcome of Phase III Study of Arzoxifene [Press Release]. Indianapolis, IN: PR Newswire, August 18, 2009.
85. Cummings SR, McClung M, Reginster JY, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 2011;26:397-404.
86. Bachmann G, Goldstein S, Lin V, Simon J, Portman D, Phelps M. Efficacy of ospemifene when used in the treatment of vulvar and vaginal atrophy for up to 52 weeks in postmenopausal women. Climacteric 2011; 14(suppl 1):92.
87. Simon J, Bachmann G, Goldstein S, Lin V, Portman D, Phelps M. Evaluation of the safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women. Climacteric 2011;14(suppl 1):87.
88. Portman D, Bachmann G, Goldstein S, et al. Efficacy of a novel SERM, ospemifene, in the treatment of moderate-to-severe vaginal dryness symptoms of vulvovaginal atrophy associated with menopause (Abstract). Menopause 2011;18:1343.
89. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. NDA 203505 Osphena approval letter, February 26, 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2013/203505Orig1s000ltr. pdf. Accessed March 21, 2013.
90. Goldstein S, Cummings S, Eastell R, Ensrud K. Vaginal effects of lasofoxifene: 3-year results from the PEARL trial (Abstract LB-5). Menopause 2008;15:1228-1229.
91. Goldstein SR, Neven P, Cummings S, et al. Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 2011;18:17-22.
92. Bachmann G, Gass M, Kagan R, Moffett A, Barcomb J, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM), improves dysparenunia in postmenopausal women with vaginal atrophy (VA). Menopause 2005;12:238.
93. Fablyn (Lasofoxifene): Cessation of Validity of the Marketing Authorisation in the European Union [Press Release]. London, England: European Medicines Agency, May 7, 2012.
94. Pfizer Inc. FABLYNA (lasofoxifene tartrate) 0.5 mg Tablets. NDA 22-242. Reproductive Health Drugs Advisory Committee Briefing Document. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4381b1-02-Pfizer.pdf. Accessed April 16, 2013.
95. Janicak PG, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry 2008; 69:222-232.